Prostaglandin G/H synthase 2

Description:

Description
  • Accession: P79208
  • Swissprot: PGH2_SHEEP
  • Organism: Ovis aries
  • Gene: PTGS2
  • Target classes: Enzyme, Unclassified

Drug Relations:

acetylsalicylic acid
The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5) Bioactivity details MOA
celecoxib
A pyrazole derivative and selective CYCLOOXYGENASE 2 INHIBITOR that is used to treat symptoms associated with RHEUMATOID ARTHRITIS; OSTEOARTHRITIS and JUVENILE ARTHRITIS, as well as the management of ACUTE PAIN. Bioactivity details MOA
dexibuprofen
Bioactivity details MOA
diclofenac
A non-steroidal anti-inflammatory agent (NSAID) with antipyretic and analgesic actions. It is primarily available as the sodium salt. Bioactivity details MOA
doconexent
a mixture of fish oil and primrose oil; used as a high-docosahexaenoic acid fatty acid supplement Bioactivity details MOA
eicosapentaenoic acid
Important polyunsaturated fatty acid found in fish oils. It serves as the precursor for the prostaglandin-3 and thromboxane-3 families. A diet rich in eicosapentaenoic acid lowers serum lipid concentration, reduces incidence of cardiovascular disorders, prevents platelet aggregation, and inhibits arachidonic acid conversion into the thromboxane-2 and prostaglandin-2 families. Bioactivity details MOA
fenbufen
an orally active nonsteroidal anti-inflammatory drug with analgesic and antipyretic activity Bioactivity details MOA
ibuprofen
A nonsteroidal anti-inflammatory agent with analgesic properties used in the treatment of RHEUMATISM and ARTHRITIS. Concerns that anti-inflammatory drugs such as ibuprofen may worsen COVID-19 circulated widely in the early months of the pandemic. FDA has stated that it is not aware of scientific evidence connecting the use of NSAIAs, such as ibuprofen, with worsening COVID-19 symptoms and will communicate publicly when more information is available. Bioactivity details MOA
indomethacin
A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES. Additional data needed to determine whether in vitro activity against SARS-CoV-2 corresponds with clinical efficacy in the treatment of COVID-19. Bioactivity details MOA
linoleic acid
A doubly unsaturated fatty acid, occurring widely in plant glycosides. It is an essential fatty acid in mammalian nutrition and is used in the biosynthesis of prostaglandins and cell membranes. (From Stedman, 26th ed) Bioactivity details MOA
linolenic acid
A fatty acid that is found in plants and involved in the formation of prostaglandins. Bioactivity details MOA
mofezolac
Cyclooxygenase 1 inhibitor; ; RN from Toxlit Bioactivity details MOA
nimesulide
Bioactivity details MOA
rofecoxib
a sulfonylphenyl furanone; withdrawn out of concern for TOXICITY Bioactivity details MOA
thalidomide
A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action. Bioactivity details MOA